ALKBH5-mediated m⁶A demethylation ameliorates extracellular matrix deposition in cutaneous pathological fibrosis

Abstract

Background: Elevated extracellular matrix (ECM) accumulation is a major contributing factor to the pathogenesis of fibrotic diseases. Recent studies have indicated that N6-methyladenosine (m⁶A) RNA modification plays a pivotal role in modulating RNA stability and contribute to the initiation of various pathological conditions. Howbeit, the precise mechanism by which m⁶A influences ECM deposition remains unclear.

Methods: In this study, we used hypertrophic scars (HTSs) as a paradigm to investigate ECM-related diseases. We focused on the role of ALKBH5-mediated m⁶A demethylation within the pathological progression of HTSs and examined its correlation with clinical stages. The effects of ALKBH5 ablation on ECM components were studied both in vivo and in vitro. Downstream targets of ALKBH5, along with their underlying mechanisms, were identified using integrated high-throughput analysis, RNA-binding protein immunoprecipitation and RNA pull-down assays. Furthermore, the therapeutic potential of exogenous ALKBH5 overexpression was evaluated in fibrotic scar models.

Results: ALKBH5 was decreased in fibroblasts derived from HTS lesions and was negatively correlated with their clinical stages. Importantly, ablation of ALKBH5 promoted the expression of COL3A1, COL1A1, and ELN, leading to pathological deposition and reconstruction of the ECM both in vivo and in vitro. From a therapeutic perspective, the exogenous overexpression of ALKBH5 significantly inhibited abnormal collagen deposition in fibrotic scar models. As determined by integrated high-throughput analysis, key ECM components including COL3A1, COL1A1, and ELN are direct downstream targets of ALKBH5. By means of its mechanism, ALKBH5 inhibits the expression of COL3A1, COL1A1, and ELN by removing m⁶A from mRNAs, thereby decreasing their stability in a YTHDF1-dependent manner.

Conclusions: Our study identified ALKBH5 as an endogenous suppressor of pathological ECM deposition, contributing to the development of a reprogrammed m6A-targeted therapy for HTSs.

Keywords

ALKBH5 / ECM / hypertrophic scar / m ⁶A modification

References

[1] Younesi FS, Miller AE, Barker TH, Rossi FMV, Hinz B. Fibroblast and myofibroblast activation in normal tissue repair and fibrosis. Nat Rev Mol Cell Biol. 2024; 25(8): 617-638.

[2] Dooling LJ, Saini K, Anlas AA, Discher DE. Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues. Matrix Biol. 2022; 111: 153-188.

[3] Wareham LK, Baratta RO, Del Buono BJ, Schlumpf E, Calkins DJ. Collagen in the central nervous system: contributions to neurodegeneration and promise as a therapeutic target. Mol Neurodegener. 2024; 19(1): 11.

[4] Li L, Fu H, Liu Y. The fibrogenic niche in kidney fibrosis: components and mechanisms. Nat Rev Nephrol. 2022; 18(9): 545-557.

[5] Jin J, Pan BH, Wang KA, et al. Subvacuum environment-enhanced cell migration promotes wound healing without increasing hypertrophic scars caused by excessive cell proliferation. Cell Prolif. 2023; 56(11): e13493.

[6] Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008; 453(7193): 314-321.

[7] Jeschke MG, Wood FM, Middelkoop E, et al. Scars. Nat Rev Dis Primers. 2023; 9(1): 64.

[8] Zhang LQ, Laato M, Muona P, Kalimo H, Peltonen J. Normal and hypertrophic scars: quantification and localization of messenger RNAs for type I, III and VI collagens. Br J Dermatol. 1994; 130(4): 453-459.

[9] Jariwala N, Ozols M, Bell M, et al. Matrikines as mediators of tissue remodelling. Adv Drug Deliv Rev. 2022; 185: 114240.

[10] Zeyer KA, Bornert O, Nelea V, et al. Dipeptidyl peptidase-4-mediated fibronectin processing evokes a profibrotic extracellular matrix. J Invest Dermatol. 2024. doi:10.1016/j.jid.2024.03.020

[11] Orsolic I, Carrier A, Esteller M. Genetic and epigenetic defects of the RNA modification machinery in cancer. Trends Genet. 2023; 39(1): 74-88.

[12] Sikorski V, Selberg S, Lalowski M, Karelson M, Kankuri E. The structure and function of YTHDF epitranscriptomic m(6)A readers. Trends Pharmacol Sci. 2023; 44(6): 335-353.

[13] Li Y, Kang X, Zhou Z, et al. The m(6)A methyltransferase Mettl3 deficiency attenuates hepatic stellate cell activation and liver fibrosis. Mol Ther. 2022; 30(12): 3714-3728.

[14] Li SR, Kang NN, Wang RR, et al. ALKBH5 SUMOylation-mediated FBXW7 m6A modification regulates alveolar cells senescence during 1-nitropyrene-induced pulmonary fibrosis. J Hazard Mater. 2024; 468: 133704.

[15] Huang X, Zhao Y, Liu D, et al. ALKBH5-mediated m(6)A demethylation fuels cutaneous wound re-epithelialization by enhancing PELI2 mRNA stability. Inflamm Regen. 2023; 43(1): 36.

[16] Moretti L, Stalfort J, Barker TH, Abebayehu D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J Biol Chem. 2022; 298(2): 101530.

[17] Forbes-Duchart L, Marshall S, Strock A, Cooper JE. Determination of inter-rater reliability in pediatric burn scar assessment using a modified version of the Vancouver Scar Scale. J Burn Care Res. 2007; 28(3): 460-467.

[18] Aarabi S, Bhatt KA, Shi Y, et al. Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. FASEB J. 2007; 21(12): 3250-3261.

[19] Ma L, Gan C, Huang Y, Wang Y, Luo G, Wu J. Comparative proteomic analysis of extracellular matrix proteins secreted by hypertrophic scar with normal skin fibroblasts. Burns Trauma. 2014; 2(2): 76-83.

[20] Shi H, Wei J, He C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol Cell. 2019; 74(4): 640-650.

[21] Wang X, Zhao BS, Roundtree IA, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015; 161(6): 1388-1399.

[22] Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021; 593(7860): 597-601.

[23] El Agha E, Moiseenko A, Kheirollahi V, et al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell. 2017; 20(2): 261-273. e3.

[24] Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature. 2020; 587(7835): 555-566.

[25] Feng Y, Guo S, Zhao Y, et al. DNA 5mC and RNA m(6)A modification successively facilitates the initiation and perpetuation stages of HSC activation in liver fibrosis progression. Cell Death Differ. 2023; 30(5): 1211-1220.

[26] Liu ZY, Lin LC, Liu ZY, Yang JJ, Tao H. m6A epitranscriptomic and epigenetic crosstalk in cardiac fibrosis. Mol Ther. 2024; 32(4): 878-889.

[27] Zhang Y, Liu Q, Ning J, et al. The proteasome-dependent degradation of ALKBH5 regulates ECM deposition in PM(2.5) exposure-induced pulmonary fibrosis of mice. J Hazard Mater. 2022; 432: 128655.

[28] Chen J, Xu C, Yang K, et al. Inhibition of ALKBH5 attenuates I/R-induced renal injury in male mice by promoting Ccl28 m6A modification and increasing Treg recruitment. Nat Commun. 2023; 14(1): 1161.

[29] He J, Cheng X, Fang B, Shan S, Li Q. Mechanical stiffness promotes skin fibrosis via Piezo1-Wnt2/Wnt11-CCL24 positive feedback loop. Cell Death Dis. 2024; 15(1): 84.

[30] Zou Z, Sepich-Poore C, Zhou X, Wei J, He C. The mechanism underlying redundant functions of the YTHDF proteins. Genome Biol. 2023; 24(1): 17.

[31] Chouhan D, Dey N, Bhardwaj N, Mandal BB. Emerging and innovative approaches for wound healing and skin regeneration: current status and advances. Biomaterials. 2019; 216: 119267.

[32] Malta MD, Cerqueira MT, Marques AP. Extracellular matrix in skin diseases: the road to new therapies. J Adv Res. 2023; 51: 149-160.

[33] Syed F, Ahmadi E, Iqbal SA, Singh S, McGrouther DA, Bayat A. Fibroblasts from the growing margin of keloid scars produce higher levels of collagen I and III compared with intralesional and extralesional sites: clinical implications for lesional site-directed therapy. Br J Dermatol. 2011; 164(1): 83-96.

[34] Keene DR, Sakai LY, Bachinger HP, Burgeson RE. Type III collagen can be present on banded collagen fibrils regardless of fibril diameter. J Cell Biol. 1987; 105(5): 2393-2402.

[35] D’Hondt S, Guillemyn B, Syx D, et al. Type III collagen affects dermal and vascular collagen fibrillogenesis and tissue integrity in a mutant Col3a1 transgenic mouse model. Matrix Biol. 2018; 70: 72-83.

[36] Chitturi P, Leask A. The role of positional information in determining dermal fibroblast diversity. Matrix Biol. 2024; 128: 31-38.

[37] Kielty CM, Sherratt MJ, Shuttleworth CA. Elastic fibres. J Cell Sci. 2002; 115(pt 14): 2817-2828.

[38] Chen K, Kwon SH, Henn D, et al. Disrupting biological sensors of force promotes tissue regeneration in large organisms. Nat Commun. 2021; 12(1): 5256.

[39] Tschumperlin DJ, Ligresti G, Hilscher MB, Shah VH. Mechanosensing and fibrosis. J Clin Invest. 2018; 128(1): 74-84.

[40] Schuster R, Younesi F, Ezzo M, Hinz B. The role of myofibroblasts in physiological and pathological tissue repair. Cold Spring Harb Perspect Biol. 2023; 15(1): a041231.

[41] Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol. 1993; 122(1): 103-111.

[42] Hong YK, Lin YC, Cheng TL, et al. TEM1/endosialin/CD248 promotes pathologic scarring and TGF-beta activity through its receptor stability in dermal fibroblasts. J Biomed Sci. 2024; 31(1): 12. doi:10.1186/s12929-024-01001-0

[43] Lee WJ, Kim YO, Choi IK, Rah DK, CO Yun. Adenovirus-relaxin gene therapy for keloids: implication for reversing pathological fibrosis. Br J Dermatol. 2011; 165(3): 673-677.

[44] Rezakhaniha R, Agianniotis A, Schrauwen JT, et al. Experimental investigation of collagen waviness and orientation in the arterial adventitia using confocal laser scanning microscopy. Biomech Model Mechanobiol. 2012; 11(3-4): 461-473.

[45] Chen K, Vigliotti A, Bacca M, McMeeking RM, Deshpande VS, Holmes JW. Role of boundary conditions in determining cell alignment in response to stretch. Proc Natl Acad Sci U S A. 2018; 115(5): 986-991.

[46] Dominissini D, Moshitch-Moshkovitz S, Salmon-Divon M, Amariglio N, Rechavi G. Transcriptome-wide mapping of N(6)-methyladenosine by m(6)A-seq based on immunocapturing and massively parallel sequencing. Nat Protoc. 2013; 8(1): 176-189.

[47] Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE, Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3’ UTRs and near stop codons. Cell. 2012; 149(7): 1635-1646.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.